Literature DB >> 21664196

Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?

Franziska A Stressmann1, Geraint B Rogers, Peter Marsh, Andrew K Lilley, Thomas W V Daniels, Mary P Carroll, Lucas R Hoffman, Graeme Jones, Collette E Allen, Nilesh Patel, Benjamin Forbes, Andrew Tuck, Kenneth D Bruce.   

Abstract

BACKGROUND: Cystic Fibrosis (CF) lung disease is characterised by an inexorable decline in lung function, punctuated by periods of symptomatic worsening known as pulmonary exacerbations (referred to here as CFPE). Despite their clinical significance, the cause of CFPE remains undetermined. It has been suggested that an increase in bacterial density may be a trigger, although this has not been shown empirically.
METHODS: Here, a previously validated quantitative PCR-based approach was used to assess numbers of Pseudomonas aeruginosa and of total bacteria in respiratory secretions from patients during the period leading up to CFPE. Sputum samples collected from 12 adult CF patients were selected retrospectively to fall approximately 21, 14, 7 and 0 days prior to CFPE diagnosis. In addition, the relationships between clinical parameters (FEV(1), temperature and patient reported outcome measures) and microbiological data were investigated.
RESULTS: No significant changes either in total bacterial or P. aeruginosa numbers were identified prior to CFPE. Of all the correlations tested, only temperature showed a significant correlation with total bacterial numbers in the period leading to CFPE.
CONCLUSIONS: These findings strongly suggest that CFPE do not generally result from increased bacterial density within the airways. Instead, data presented here are consistent with alternative models of pulmonary exacerbation.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21664196     DOI: 10.1016/j.jcf.2011.05.002

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  66 in total

1.  Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period.

Authors:  Joshua R Stokell; Raad Z Gharaibeh; Timothy J Hamp; Malcolm J Zapata; Anthony A Fodor; Todd R Steck
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

Review 2.  The Microbiome and the Respiratory Tract.

Authors:  Robert P Dickson; John R Erb-Downward; Fernando J Martinez; Gary B Huffnagle
Journal:  Annu Rev Physiol       Date:  2015-11-02       Impact factor: 19.318

Review 3.  The microbiome and critical illness.

Authors:  Robert P Dickson
Journal:  Lancet Respir Med       Date:  2015-12-12       Impact factor: 30.700

Review 4.  The role of the microbiome in exacerbations of chronic lung diseases.

Authors:  Robert P Dickson; Fernando J Martinez; Gary B Huffnagle
Journal:  Lancet       Date:  2014-08-23       Impact factor: 79.321

5.  Getting Our Fingers on the Pulse of Slow-Growing Bacteria in Hard-To-Reach Places.

Authors:  Tara Gallagher; Joann Phan; Katrine Whiteson
Journal:  J Bacteriol       Date:  2018-11-26       Impact factor: 3.490

6.  Changes in cystic fibrosis airway microbiota at pulmonary exacerbation.

Authors:  Lisa A Carmody; Jiangchao Zhao; Patrick D Schloss; Joseph F Petrosino; Susan Murray; Vincent B Young; Jun Z Li; John J LiPuma
Journal:  Ann Am Thorac Soc       Date:  2013-06

7.  The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Zakuan Z Deris; Heidi H Yu; Kathryn Davis; Rachel L Soon; Jovan Jacob; Caron K Ku; Anima Poudyal; Phillip J Bergen; Brian T Tsuji; Jurgen B Bulitta; Alan Forrest; David L Paterson; Tony Velkov; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

8.  Stenotrophomonas maltophilia Differential Gene Expression in Synthetic Cystic Fibrosis Sputum Reveals Shared and Cystic Fibrosis Strain-Specific Responses to the Sputum Environment.

Authors:  Graham G Willsey; Korin Eckstrom; Annette E LaBauve; Lauren A Hinkel; Kristin Schutz; Robert J Meagher; John J LiPuma; Matthew J Wargo
Journal:  J Bacteriol       Date:  2019-07-10       Impact factor: 3.490

Review 9.  The respiratory microbiome of HIV-infected individuals.

Authors:  M B Lawani; A Morris
Journal:  Expert Rev Anti Infect Ther       Date:  2016-08       Impact factor: 5.091

Review 10.  Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.

Authors:  Matthew Hurley; Alan Smyth
Journal:  Ther Adv Respir Dis       Date:  2012-09-11       Impact factor: 4.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.